摘要
目的:研究TAC方案联合西黄丸对Ⅲ期乳腺癌患者P53、HER-2、TOPⅡ影响。方法:回顾性分析2014年3月至2016年2月在本院进行治疗的ⅡI期乳腺癌患者78例,根据治疗方法分为对照组和观察组。对照组患者采用TAC方案治疗,观察组患者采用TAC方案联合西黄丸治疗。评价两组患者的临床疗效、治疗前和治疗后P53基因(P53)、人表皮生长因子受体-2(HER-2)、拓扑异构酶Ⅱ(TOP-Ⅱ)表达情况,以及雌激素水平。结果:观察组总有效率显著高于对照组(P<0.05)。观察组和对照组的P53水平比较无显著性差异(P>0.05)。观察组HER-2、TOP Ⅱ阳性表达率显著低于对照组(P<0.05)。治疗后,观察组促黄体生成素(LH)、促卵泡生成素(FSH)水平显著高于对照组(P<0.05),血清雌酮(E1)、雌二醇(E2)水平显著低于对照组(P<0.05)。结论:TAC方案联合西黄丸治疗ⅡI期乳腺癌可有效改善患者雌激素水平,降低HER-2及TOPⅡ阳性表达率,值得推广应用。
Objective： To study the effect of TAC scheme combined with xihuangwan on the levels of P53 gene, human epidermal growth factor receptor 2 and topoisomerase II on breast cancer patients. Methods： We retrospectively analyzed the patients with stage III breast cancer who were treated in our hospital from March 2014 to February 2016. The patients treated by TAC regimen were regarded as the control group. The patients treated by TAC plus Xihuang Pill were the observation group. The clinical efficacy of two groups was evaluated. P53, human epidermal growth factor receptor - 2 （HER - 2） and topoisomerase II （TOP - II）, and estrogen levels were measured before and after treatment in the two groups. Results： After treatment, the total effective rate in the observation group was significantly higher than that in the control group （P 〈0.05）. There was no significant difference between the observation group and the control group （P〉 0.05）. The positive rates of HER-2 and TOP II in the observation group were significantly lower than those in the control group （P 〈0.05）. After treatment, the levels of luteinizing hormone （LH） and follicle stimulating hormone （FSH） in the observation group were significantly higher than those in the control group （P 〈0.05）, serum estrone （El）, estradiol （E2） level significantly lower than the control group （P 〈0.05）. Conclusions： TAC scheme and xihuangwan can effectively improve the levels of estrogen in patients with stage III breast cancer, and decrease the ehrs - 2 and TOPII positive expressions, which is worthy of clinical application.
出处
《现代生物医学进展》
CAS
2017年第8期1505-1508,共4页
Progress in Modern Biomedicine
基金
四川省卫生厅科研基金项目(00096)
